Product Liability & Toxic Torts
This week we focus on pharmaceutical litigation: a ruling that failure-to-warn claims brought against generic drug makers are pre-empted by federal law, a look at why drug manufacturers who comply with FDA labeling regulations are granted a rebuttable presumption that their labeling is adequate, and some practical pointers for litigators of product-liability cases.
This premium content is reserved for New Jersey Law Journal subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now